SMAD4 and neoplasm: Other tumours carrying a high percentage of mutations in key components of the canonical signalling, such as pancreatic cancer40 or extrahepatic CCA,41 in which SMAD4 is one of the most mutated genes, could benefit from the use of these inhibitors.